Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 19/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6191044 | 0.96 | CCR5 (0.68) | CCR5CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL6186206 | 0.96 | CCR5 (0.68) | CCR5CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL6188779 | 0.93 | CCR5 (0.65) | CCR5CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL6189376 | 0.93 | CCR5 (0.64) | CCR5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5343303 | 0.92 | CCR5 (0.79) | CCR5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5349389 | 0.92 | CCR5 (0.78) | CCR5CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL5356844 | 0.92 | CCR5 (0.79) | CCR5CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL5347754 | 0.92 | CCR5 (0.79) | CCR5CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5349581 | 0.92 | CCR5 (0.63) | CCR5CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL6190166 | 0.92 | CCR5 (0.63) | CCR5CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267114-A1 | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-01 | — | — | US | disclosed |
| EP-1541574-A1 | TRIAZASPIRO 5.5 UNDECANE DERIVATIVES AND DRUGS COMPRISI NG THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267114-A1 | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | HLA-DRB1, TLR5, HLA-C | CCR5 350/4885CYP3A4 1982/4885CYP2D6 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.